| A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants (NCT06294288) | Longbio Pharma | 2022-07-13 |
| A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria (NCT05335499) | Taiho Pharmaceutical Co., Ltd. | 2022-06-28 |
| Improving Health and Wellbeing for People Diagnosed With Chronic Spontaneous Urticaria (CSU) (NCT06108869) | Royal College of Surgeons, Ireland | 2022-06-01 |
| A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria (NCT05368285) | Celldex Therapeutics | 2022-05-19 |
| Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria. (NCT05373355) | Hangzhou Highlightll Pharmaceutical Co., Ltd | 2022-05-10 |
| STOP CSUA: phySical acTivity, mOod and sleeP in Chronic Spontaneous Urticaria and Angioedema (NCT05169645) | St. James's Hospital, Ireland | 2022-02-01 |
| A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines (NCT05048342) | Novartis Pharmaceuticals | 2022-01-15 |
| A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines (NCT05032157) | Novartis Pharmaceuticals | 2021-12-01 |
| A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines (NCT05030311) | Novartis Pharmaceuticals | 2021-11-30 |
| Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine (NCT05107115) | Sanofi | 2021-11-24 |
| Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria (NCT04944602) | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 2021-07-01 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria (NCT04827589) | Gilead Sciences | 2021-07-01 |
| Efficacy of Low-dose Interleukin-2 Treatment in Chronic Spontaneous Urticaria (NCT04893980) | Second Xiangya Hospital of Central South University | 2021-06-16 |
| Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria (NCT04833855) | Amgen | 2021-04-15 |
| To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria (NCT04426890) | Celltrion | 2020-12-09 |
| A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO) (NCT04612725) | AstraZeneca | 2020-10-27 |
| A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria (NCT04538794) | Celldex Therapeutics | 2020-09-24 |
| Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria (NCT04513548) | Novartis Pharmaceuticals | 2020-08-05 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants (NCT04444466) | UCB Biopharma SRL | 2020-06-30 |
| Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab (NCT04210843) | Novartis Pharmaceuticals | 2020-04-08 |
| Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients (NCT04439955) | Stero Biotechs Ltd. | 2020-02-01 |
| Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID) (NCT04180488) | Sanofi | 2019-12-11 |
| Tranexamic Acid and Spontaneous Chronic Urticaria (NCT03789422) | University Hospital, Grenoble | 2019-12-10 |
| A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria (NCT04159701) | Eli Lilly and Company | 2019-11-15 |
| An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU (NCT04109313) | Novartis Pharmaceuticals | 2019-10-24 |
| Mepolizumab for the Treatment of Chronic Spontaneous Urticaria (NCT03494881) | Mayo Clinic | 2019-07-30 |
| This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines (NCT03926611) | Novartis Pharmaceuticals | 2019-06-06 |
| Frequency of Parasite Infestation in Patients With Chronic Spontaneous Urticaria (NCT04314999) | University Hospital, Basel, Switzerland | 2019-06-01 |
| A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines (NCT03907878) | Novartis Pharmaceuticals | 2019-04-13 |
| A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC (NCT03661866) | Target PharmaSolutions, Inc. | 2018-12-21 |
| Dupilumab in Chronic Spontaneous Urticaria (NCT03749135) | Charite University, Berlin, Germany | 2018-11-12 |
| A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. (NCT03580356) | Novartis Pharmaceuticals | 2018-10-20 |
| A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines (NCT03580369) | Novartis Pharmaceuticals | 2018-10-17 |
| Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU) (NCT03437278) | Novartis Pharmaceuticals | 2018-08-01 |
| Shotblocker® Use in Subcutaneous Injection (NCT04210323) | Saglik Bilimleri Universitesi | 2018-06-05 |
| Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria (NCT03328897) | Novartis Pharmaceuticals | 2017-04-26 |
| A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients (NCT02649218) | Novartis Pharmaceuticals | 2016-05-24 |
| Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU (NCT02477332) | Novartis Pharmaceuticals | 2015-07-15 |
| Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria (NCT02372604) | Hospices Civils de Lyon | 2015-07-01 |
| Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment (NCT02550106) | Novartis Pharmaceuticals | 2015-04-22 |
| OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients (NCT02161562) | Novartis Pharmaceuticals | 2014-08-01 |
| Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy (NCT01723072) | Novartis Pharmaceuticals | 2013-01-23 |
| Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients (NCT01803763) | Insel Gruppe AG, University Hospital Bern | 2012-09-01 |
| Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria (NCT05170724) | Novartis Pharmaceuticals | |
| Global Managed Access Program Cohort for Ligelizumab in CSU (NCT04903613) | Novartis Pharmaceuticals | |